Back

Treatment Effects of Cholinesterase Inhibitors in Alzheimer's Disease: a Causal Machine Learning Approach

Geoffroy, C.; Dedebant, E.; Hauw, F.; Fauvel, T.; Tornqvist, M.

2026-02-12 pharmacology and therapeutics
10.64898/2026.02.11.26346078 medRxiv
Show abstract

AO_SCPLOWBSTRACTC_SCPLOWO_ST_ABSINTRODUCTIONC_ST_ABSTreatment response in Alzheimers disease (AD) varies substantially across patients, yet no validated frameworks exist to estimate heterogeneous treatment effects (HTE) from observational data while controlling for confounding bias. METHODSWe developed a causal machine learning framework integrating expert-guided causal graphs, complementary HTE estimators, sensitivity analyses, and policy learning. We applied it to cholinesterase inhibitors (ChEIs) in MCI due to AD to patients from the NACC and ADNI cohorts. RESULTSAnalysing 4,049 patients with 12-month and 2,223 with 36-month follow-up, all estimators indicated null or negative long-term ChEI effects on cognitive and functional outcomes, notably on functional measures. ChEIs showed slightly more deleterious effects among men than women. DISCUSSIONThis framework provides a methodology for estimating HTE from observational data. It revealed no beneficial responder subgroups, highlighting the challenge of detecting treatment heterogeneity in moderately sized cohorts. This approach can inform treatment selection for other AD therapies including memantine, anti-amyloid agents, and emerging treatments.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Alzheimer's & Dementia: Translational Research & Clinical Interventions
16 papers in training set
Top 0.1%
22.9%
2
Alzheimer's & Dementia
143 papers in training set
Top 0.7%
10.3%
3
Alzheimer's Research & Therapy
52 papers in training set
Top 0.1%
8.6%
4
NeuroImage: Clinical
132 papers in training set
Top 0.6%
6.9%
5
Journal of Alzheimer’s Disease
39 papers in training set
Top 0.3%
3.7%
50% of probability mass above
6
Nature Communications
4913 papers in training set
Top 39%
3.7%
7
NeuroImage
813 papers in training set
Top 3%
3.7%
8
PLOS ONE
4510 papers in training set
Top 38%
3.7%
9
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
38 papers in training set
Top 0.5%
2.4%
10
The British Journal of Psychiatry
21 papers in training set
Top 0.4%
2.1%
11
The Lancet Infectious Diseases
71 papers in training set
Top 1%
1.9%
12
GeroScience
97 papers in training set
Top 1.0%
1.7%
13
Journal of Biomedical Informatics
45 papers in training set
Top 0.9%
1.5%
14
Human Brain Mapping
295 papers in training set
Top 3%
1.1%
15
The Journal of Prevention of Alzheimer's Disease
10 papers in training set
Top 0.3%
1.0%
16
Molecular Therapy
71 papers in training set
Top 2%
1.0%
17
Scientific Reports
3102 papers in training set
Top 70%
0.9%
18
npj Genomic Medicine
33 papers in training set
Top 0.8%
0.8%
19
npj Digital Medicine
97 papers in training set
Top 3%
0.8%
20
PLOS Medicine
98 papers in training set
Top 4%
0.8%
21
Neurobiology of Aging
95 papers in training set
Top 2%
0.8%
22
Nature Aging
51 papers in training set
Top 2%
0.7%
23
Frontiers in Artificial Intelligence
18 papers in training set
Top 0.8%
0.7%
24
Nature Medicine
117 papers in training set
Top 6%
0.7%
25
Advanced Science
249 papers in training set
Top 21%
0.7%
26
Frontiers in Pharmacology
100 papers in training set
Top 5%
0.7%
27
BMC Medical Research Methodology
43 papers in training set
Top 2%
0.7%
28
Atherosclerosis
29 papers in training set
Top 1%
0.7%
29
Communications Medicine
85 papers in training set
Top 1%
0.7%
30
iScience
1063 papers in training set
Top 40%
0.5%